Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease (REVERSE-SD)
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Sponsor: Amsterdam UMC, location VUmc
Listed as NCT03402659, this PHASE2 trial focuses on Alzheimer Disease and remains completed. Sponsored by Amsterdam UMC, location VUmc, it has been updated 16 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 11 earlier versions
-
May 2022 — Dec 2022 [monthly]
Completed PHASE2
-
Nov 2021 — May 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — May 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amsterdam UMC, location VUmc
- EIP Pharma Inc
- Worldwide Clinical Trials
For direct contact, visit the study record on ClinicalTrials.gov .